Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Israel

European Research Council grant · Running

MiTE Developing the next generation of cis-targeting macrophage-T cell cancer immunotherapies

Coordinator
Weizmann Institute of Science, Israel
Runs
1 June 2023 to 31 May 2025
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101123436

What the project is doing

In the project's own words, from its summary on CORDIS.

Immunotherapy holds great promise for the curative treatment of millions of cancer patients, with a market size of over 100 billion USD today, which is expected to at least double in the next decade. Cancer immunotherapies are designed either to promote anti-tumor immune activity in the tumor microenvironment (TME), via molecules such as cytokines and antibodies, or to inhibit negative T cell signals induced by cancer and antigen-presenting cells (APCs) in the TME, an approach known as immune checkpoint blockade (ICB).

Yet current immunotherapies have shown significant clinical success only against a limited number of cancers, for two major reasons: insufficient anti-tumor immune activation or severe side effects and toxicity as a result of nonspecific immune activation. We propose to overcome these two challenges through the development of a novel class of molecules capable of simultaneously modulating the myeloid and lymphoid immune cell compartments in the TME and generating a highly specific and extremely potent antitumor immune response.

In this PoC grant, we seek to validate the ability to construct such dual-modulatory agents, which will provide us with the proof-of-concept for these technologies.

Topics

Who is involved

OrganisationCityCountryRole
Weizmann Institute of ScienceRehovotIsraelCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI